SG11202012787PA - Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof - Google Patents

Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof

Info

Publication number
SG11202012787PA
SG11202012787PA SG11202012787PA SG11202012787PA SG11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA
Authority
SG
Singapore
Prior art keywords
dihydroquinolin
cyclobutoxy
methanone
pyrazol
piperidin
Prior art date
Application number
SG11202012787PA
Other languages
English (en)
Inventor
George P Luke
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of SG11202012787PA publication Critical patent/SG11202012787PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202012787PA 2018-06-29 2019-06-28 Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof SG11202012787PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692554P 2018-06-29 2018-06-29
US201862692546P 2018-06-29 2018-06-29
PCT/US2019/039677 WO2020006329A1 (fr) 2018-06-29 2019-06-28 Sels de (s)-(5-cyclobutoxy-2-méthyl-6-(1- (pipéridin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)méthanone et leurs formes solides

Publications (1)

Publication Number Publication Date
SG11202012787PA true SG11202012787PA (en) 2021-01-28

Family

ID=68984963

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012787PA SG11202012787PA (en) 2018-06-29 2019-06-28 Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof

Country Status (12)

Country Link
US (1) US20210261528A1 (fr)
EP (1) EP3813835A4 (fr)
JP (1) JP2021529764A (fr)
KR (1) KR20210025615A (fr)
CN (1) CN112584835A (fr)
AU (1) AU2019293260A1 (fr)
BR (1) BR112020026359A2 (fr)
CA (1) CA3103153A1 (fr)
IL (1) IL279673A (fr)
MX (1) MX2020013636A (fr)
SG (1) SG11202012787PA (fr)
WO (1) WO2020006329A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003163A1 (fr) 2019-07-01 2021-01-07 Forma Therapeutics, Inc. Traitement du cancer au moyen d'un inhibiteur de la famille des protéines à bromodomaine et à domaine extra-terminal (bet)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055027A2 (fr) * 2008-11-11 2010-05-20 Novartis Ag Composés organiques
US20160256448A1 (en) * 2013-11-18 2016-09-08 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
EP3071203B1 (fr) * 2013-11-18 2020-12-23 Forma Therapeutics, Inc. Compositions de tétrahydroquinoline utilisées comme inhibiteurs de protéines à bromodomaine et domaine extraterminal (bet)

Also Published As

Publication number Publication date
US20210261528A1 (en) 2021-08-26
MX2020013636A (es) 2021-03-25
EP3813835A1 (fr) 2021-05-05
KR20210025615A (ko) 2021-03-09
IL279673A (en) 2021-03-01
BR112020026359A2 (pt) 2021-03-30
CA3103153A1 (fr) 2020-01-02
AU2019293260A1 (en) 2021-01-07
JP2021529764A (ja) 2021-11-04
WO2020006329A1 (fr) 2020-01-02
EP3813835A4 (fr) 2022-03-02
CN112584835A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
SG11202100410YA (en) Splittable security token
ZA201707423B (en) Imidazolonyl quinolines and use thereof as atm kinase inhibitors
IL248924A0 (en) 1-((r4,s3)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidine-3-yl)-3-(4-methyl-3-(2-methylpyrimidine-5-yl)- 1-phenyl-h1-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3351122A4 (fr) Embout de cigarette électronique, cartouche de liquide à vapoter et cigarette électronique
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-converted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
HK1211576A1 (en) Salts and solid forms of (s) -3-(4-((4-morpholinomethyl)benzyl)oxy)- 1-oxoisoindolin-2-yl) piperidine-2,6-dione and compositions comprising and methods of using the same (s)-3-(4-((4-()))-1--2-)-26-
EP3376865A4 (fr) 4-((6-(2,4-difluorophényl)-1,1-difluoro-2-hydroxy-3-(1h
ZA201606386B (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
HK1258996A1 (zh) 新型fyn激酶抑制劑的方法、組合物以及用途
SG11201600996UA (en) Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
IL270753A (en) Nanoporous sequences
IL279673A (en) Salts of (S)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-4,3-dihydroquinolin-1(2H)-yl) (cyclopropyl)methanone and their solid forms
EP3541796A4 (fr) 4-((6-(2,4-difluorophényl)-1,1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile et procédés de préparation
SG11201809760TA (en) Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
EP3553059A4 (fr) Bromhydrate de dérivé de benzodiazépine, son procédé de préparation et son utilisation
HK1254741A1 (zh) (4-((3r，4r)-3-甲氧基四氫-吡喃-4-基氨基)哌啶-1-基)(5-甲基-6-(((2r，6s)-6-(對-甲苯基)四氫-2h-吡喃-2-基)甲基氨基)嘧啶-4-基)甲酮檸檬酸鹽
EP3233824A4 (fr) Compositions de (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-méthyl-1h-1,2,4-triazol-3-yl)phényl)-3,6-dihydropyridin-1 (2h)-yl)-2-oxoéthyl)-3-(méthylthio)pyrrolidine -3-carboxamide pour préparations pharmaceutiques
EP3233079A4 (fr) Compositions de (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-méthyl-1h-1,2,4-triazol-3-yl)phényl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoéthyl)-3- (méthylthio)pyrrolidine-3-carboxamide pour préparations pharmaceutiques
EA202190154A1 (ru) Соли (s)-(5-циклобутокси-2-метил-6-(1-(пиперидин-4-ил)-1h-пиразол-4-ил)-3,4-дигидрохинолин-1(2h)-ил)(циклопропил)метанона и его твердые формы
IL257734B (en) -(cyclopropylmethyl)-4-(3,3,3-trifluoropropanoyl)octahydro-1h-6,2-methanopyrrolo[3,2-b]pyridin-3-ylpivalates and their synthesis
HK1226182A1 (zh) 一種提供請求信息的方法及用戶終端